Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Antiviral activity against Human rhinovirus serotype 39 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect after 24 to 36 hrs by MTT assay
Assay data:3 Active, 1 Activity ≤ 1 µM, 11 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed Citation
Inhibition of Human rhinovirus serotype 39 capsid infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect at 5 ug/ml treated with virus inoculum measured after 24 to 36 hrs relative to control
Assay data:1 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of Human rhinovirus serotype 39 capsid infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect at 5 ug/ml treated 1 hr prior to viral infection measured 24 to 36 hrs post viral infection relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of Human rhinovirus serotype 39 capsid infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect at 5 ug/ml treated 1 hr post viral infection measured after 24 to 36 hrs relative to control
Inhibition of Human rhinovirus serotype 39 capsid infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect at 5 ug/ml treated 2 hrs post viral infection measured after 24 to 36 hrs relative to control
Inhibition of Human rhinovirus serotype 39 capsid infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect at 5 ug/ml treated 3 hrs post viral infection measured after 24 to 36 hrs relative to control
Antiviral activity against Human rhinovirus 39 assessed as reduction in virus yield after 24 to 36 hrs by agar plaque assay
Assay data:11 Tested
SummaryPubMed Citation
Antienteroviral activity against Human rhinovirus 39 infected in human HeLa Rh cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Antiviral activity against Human rhinovirus 39 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS-based CPE reduction assay
Antiviral activity against HRV39 with 3C protease S105T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 9 passages for 50 days by XTT assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 5 passages for 29 days by XTT assay
Antiviral activity against wild type HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 days by XTT assay
Ratio of EC50 for HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells
Ratio of EC50 for HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells after 5 passages for 29 days to EC50 for wild type HRV39 infected in human H1-HeLa cells
Antiviral activity against HRV39 with 3C protease S105S/T, N130K, L136F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 6 passages for 33 days by XTT assay
Antiviral activity against HRV39 with 3C protease N130NB/K, L136/F mutation infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 4 passages for 24 days by XTT assay
Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 3 passages for 14 days by XTT assay
Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 2 passages for 12 days by XTT assay
Antiviral activity against HRV39 infected in human H1-HeLa cells assessed as virus-induced cytopathic effect after 1 passage for 7 days by XTT assay
Ratio of EC50 for HRV39 infected in human H1-HeLa cells after 9 passages for 50 days to EC50 for wild type HRV39 infected in human H1-HeLa cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on